Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03407144 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
A Phase 2 study of Hodgkin Lymphoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 340
- Enrollment target
- 20
- Study locations
NCT03407144 is a Phase 2 study of Hodgkin Lymphoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 340 participants, above the 161-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (111% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT03407144, a Phase 2 study of Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 340 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
Conditions Studied
Interventions
- BIOLOGICAL pembrolizumab
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG vinblastine
- DRUG dacarbazine
Study Locations (20)
California
- Kaiser - Orange County ( Site 0084) - Anaheim
- Kaiser Permanente ( Site 0082) - Downey
- Kaiser - Fontana ( Site 0083) - Fontana
- MemorialCare Health System - Long Beach Medical Center-Cherese Mari Laulhere Children's Village ( Si - Long Beach
- Kaiser Permanente Downey Medical Center ( Site 0024) - Los Angeles
- Kaiser Permanente - Oakland ( Site 0047) - Oakland
- Kaiser Permanente - Roseville ( Site 0080) - Roseville
- Kaiser Permanente - Santa Clara ( Site 0079) - Santa Clara
Florida
- University of Florida ( Site 0051) - Gainesville
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital ( Site 0048) - Hollywood
- Arnold Palmer Hospital ( Site 0065) - Orlando
Connecticut
- Connecticut Children's Medical Center ( Site 0045) - Hartford
- Yale Cancer Center ( Site 0061) - New Haven
Alabama
- Children's Hospital of Alabama ( Site 0023) - Birmingham
Arizona
- Phoenix Childrens Hospital ( Site 0034) - Phoenix
Arkansas
- Arkansas Children's Hospital ( Site 0046) - Little Rock
Colorado
- Children's Hospital - Colorado ( Site 0028) - Aurora
District of Columbia
- Children's National Medical Center ( Site 0090) - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2018-04-09 |
| Est. Completion | 2026-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03407144
The ClinicalTrials.gov registry entry for NCT03407144 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 161-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (111% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.
NCT03407144 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03407144 about?
NCT03407144 is a clinical study titled "Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)". This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
What is the current status of trial NCT03407144?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2018-04-09. Estimated completion is 2026-11-06.
What conditions does trial NCT03407144 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT03407144?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), cyclophosphamide (DRUG), doxorubicin (DRUG), vinblastine (DRUG), dacarbazine (DRUG).
Who is sponsoring clinical trial NCT03407144?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03407144 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.